These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9627133)

  • 21. Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.
    Takahashi M; Tack BF; Nussenzweig V
    J Exp Med; 1977 Jan; 145(1):86-100. PubMed ID: 830792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of properdin in zymosan- and Escherichia coli-induced complement activation.
    Harboe M; Garred P; Lindstad JK; Pharo A; Müller F; Stahl GL; Lambris JD; Mollnes TE
    J Immunol; 2012 Sep; 189(5):2606-13. PubMed ID: 22851705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).
    Saggu G; Cortes C; Emch HN; Ramirez G; Worth RG; Ferreira VP
    J Immunol; 2013 Jun; 190(12):6457-67. PubMed ID: 23677468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Covalent linkage of C3 to properdin during complement activation.
    Whiteman LY; Purkall DB; Ruddy S
    Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement-mediated inhibition of immune precipitation. II. Analysis by sucrose density gradient ultracentrifugation.
    Schifferli JA; Peters DK
    Clin Exp Immunol; 1982 Mar; 47(3):563-9. PubMed ID: 6919473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement alternative pathway activation in human nonalcoholic steatohepatitis.
    Segers FM; Verdam FJ; de Jonge C; Boonen B; Driessen A; Shiri-Sverdlov R; Bouvy ND; Greve JW; Buurman WA; Rensen SS
    PLoS One; 2014; 9(10):e110053. PubMed ID: 25299043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Properdin binding to complement activating surfaces depends on initial C3b deposition.
    Harboe M; Johnson C; Nymo S; Ekholt K; Schjalm C; Lindstad JK; Pharo A; Hellerud BC; Nilsson Ekdahl K; Mollnes TE; Nilsson PH
    Proc Natl Acad Sci U S A; 2017 Jan; 114(4):E534-E539. PubMed ID: 28069958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of the alternative pathway of complement in the newborn infant.
    Adamkin D; Stitzel A; Urmson J; Farnett ML; Post E; Spitzer R
    J Pediatr; 1978 Oct; 93(4):604-8. PubMed ID: 702236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement activation by tubular cells is mediated by properdin binding.
    Gaarkeuken H; Siezenga MA; Zuidwijk K; van Kooten C; Rabelink TJ; Daha MR; Berger SP
    Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1397-403. PubMed ID: 18753294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    Schreiber RD; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normal human serum depleted of C1q, factor D and properdin: its use in studies of complement activation.
    Sjöholm AG; Selander B; Ostenson S; Holmström E; Söderström C
    APMIS; 1991 Dec; 99(12):1120-8. PubMed ID: 1772649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.
    Sissons JG; Oldstone MB; Schreiber RD
    Proc Natl Acad Sci U S A; 1980 Jan; 77(1):559-62. PubMed ID: 6928644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
    Hourcade DE
    J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partial properdin deficiency.
    Davis CA; Forristal J
    J Lab Clin Med; 1980 Oct; 96(4):633-9. PubMed ID: 6903190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.
    Vuagnat BB; Mach J; Le Doussal JM
    Mol Immunol; 2000 Jun; 37(8):467-78. PubMed ID: 11090881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.